Close
Digital Health & Ai Innovation summit 2026
Medical Taiwan 2026

Max Healthcare to acquire 76% stake in Pushpanjali Crosslay for Rs 287 crore

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

China Approves First Commercial Brain-Computer Interface

China has granted approval for the commercial sale of...

MiniMed 780G System Gains CE Mark...

MiniMed Group, a global provider of integrated insulin delivery...

SmartHeart, the Cardiac MR Suite by...

Philips received FDA 510(k) clearance for SmartHeart, which happens...

Max Healthcare Institute Ltd (MHC) has inked agreements to acquire 76 per cent stake in NCR-based Pushpanjali Crosslay Hospital for Rs 287 crore.
"Max Healthcare Institute Ltd. has executed definitive agreements on May 28, 2015 to acquire a controlling stake of 76 per cent in NCR based Pushpanjali Crosslay Hospital (PCH) through a combination of fresh investment and acquisition of shares from existing promoters for an aggregate sum of Rs 287 crore," diversified group Max India said in a filing to BSE.
MHC is an equal joint-venture between Max India and Life Healthcare, South Africa, with both shareholders holding 46 per cent stake each in it, said the filing.
The 340-bed Pushpanjali Crosslay is located along the East Delhi-Ghaziabad-Noida corridor. It has the capacity to expand up to 540 beds and is NABH and NABL accredited. It has been operational since 2010, Max India said.
The hospital had reported revenue of Rs 143 crore at an EBIDTA margin of 14 per cent in FY 2014.
Max India stock was trading at Rs 469.05, down 2.32 per cent, on the BSE.

MEDICAL FAIR ASIA 2026

Latest stories

Related stories

China Approves First Commercial Brain-Computer Interface

China has granted approval for the commercial sale of...

MiniMed 780G System Gains CE Mark for Abbott Instinct Sensor

MiniMed Group, a global provider of integrated insulin delivery...

SmartHeart, the Cardiac MR Suite by Philips Gets Clearance

Philips received FDA 510(k) clearance for SmartHeart, which happens...

Medtronic Neurovascular Portfolio Strengthens with Scientia

Medtronic, on March 10, 2026, announced a definitive agreement...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »